Arrhythmia Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Arrhythmia refers to any abnormality in the rate, rhythm, or electrical conduction of the heart. The term encompasses a broad spectrum of conditions — from benign ectopic beats to life-threatening ventricular fibrillation — and the appropriate treatment strategy depends critically on the specific arrhythmia type, its haemodynamic consequences, the patient's underlying heart disease, and the risk of sudden cardiac death.

The electrical system of the heart generates impulses in the sinoatrial (SA) node, conducts them through the atrioventricular (AV) node, and spreads them via the bundle of His and Purkinje fibres to the ventricular myocardium. Arrhythmias arise from disorders of impulse formation (abnormal automaticity or triggered activity), impulse conduction (re-entry circuits), or both. The most common clinically significant arrhythmia is atrial fibrillation (AF), which affects 2–3% of the general population and is the leading preventable cause of cardioembolic stroke.

Arrhythmia treatment has three primary goals: relief of symptoms (palpitations, breathlessness, syncope), prevention of thromboembolic complications (particularly stroke in AF), and reduction of sudden cardiac death risk (in ventricular arrhythmias and structural heart disease). Treatment modalities include pharmacological therapy (antiarrhythmic drugs, rate-control agents, anticoagulants), catheter-based interventions (ablation), and device therapy (pacemakers, implantable cardioverter-defibrillators — ICDs, cardiac resynchronisation therapy — CRT).

Atrial fibrillation (AF) is the most prevalent arrhythmia treated in clinical practice. It is characterised by chaotic atrial electrical activity producing an irregularly irregular ventricular rate. Management addresses three domains: rate control (slowing ventricular response), rhythm control (restoring and maintaining sinus rhythm), and stroke prevention (anticoagulation with warfarin or direct oral anticoagulants — DOACs — based on CHA2DS2-VASc score assessment).

Supraventricular tachycardias (SVTs) — including AV nodal re-entrant tachycardia (AVNRT), AV re-entrant tachycardia (AVRT) in Wolff-Parkinson-White syndrome, and atrial flutter — are typically managed with vagal manoeuvres and adenosine acutely, and catheter ablation for curative long-term management. Ventricular arrhythmias — ventricular tachycardia (VT) and ventricular fibrillation (VF) — represent the primary mechanism of sudden cardiac death and require urgent management. Bradyarrhythmias including sick sinus syndrome and high-degree AV block are treated with permanent cardiac pacing.

Any patient with confirmed arrhythmia causing symptoms, haemodynamic compromise, thromboembolic risk, or sudden cardiac death risk is a candidate for specific treatment. Risk stratification tools guide treatment decisions: CHA2DS2-VASc score for AF stroke risk (score ≥2 in men, ≥3 in women typically warrants anticoagulation); CHADS-VASc anticoagulation decision; HAS-BLED score for bleeding risk assessment. Ejection fraction (EF) is a key indicator — patients with EF below 35% are candidates for ICD implantation after adequate medical therapy.

Catheter ablation for AF is indicated in patients with symptomatic paroxysmal or persistent AF in whom at least one antiarrhythmic drug has failed or is not tolerated, and in selected patients as first-line therapy. For SVT, ablation is considered first-line in patients preferring curative treatment over lifelong medication. Pacemaker implantation is indicated in symptomatic sinus node dysfunction and second- or third-degree AV block. Contraindications are procedure-specific: ablation is generally avoided during active infection or decompensated heart failure; anticoagulation is contraindicated in active major haemorrhage.

Rate control in AF aims to keep resting heart rate below 110 bpm (lenient target per ESC 2020 guidelines) using beta-blockers (bisoprolol, metoprolol), rate-limiting calcium channel blockers (diltiazem, verapamil — contraindicated in heart failure with reduced EF), or digoxin. Rhythm control aims to restore and maintain sinus rhythm using antiarrhythmic drugs (flecainide in structurally normal hearts; sotalol; amiodarone for structural heart disease) or electrical cardioversion (DC cardioversion — DCCV).

Catheter ablation — delivered via transfemoral venous access under fluoroscopic and electroanatomical mapping guidance — is the most transformative interventional arrhythmia treatment. Pulmonary vein isolation (PVI) is the cornerstone of AF ablation, achieved through radiofrequency energy or cryoablation (Arctic Front), with point-by-point or single-shot circumferential lesion sets around the pulmonary vein ostia. SVT ablation (AVNRT, AVRT) achieves cure rates of 95% with catheter ablation. VT ablation in ischaemic and non-ischaemic cardiomyopathy reduces VT burden and appropriate ICD shocks.

Device therapy: permanent pacemakers (single-chamber, dual-chamber, or MRI-conditional) are implanted transvenously under local anaesthesia for bradyarrhythmias. ICDs provide life-saving therapy for sudden cardiac death prevention in primary prevention (EF ≤35% with NYHA Class II-III symptoms) and secondary prevention (survivors of VF or sustained VT with haemodynamic compromise). Cardiac resynchronisation therapy (CRT-P or CRT-D) improves symptoms, QoL, and mortality in heart failure patients with wide QRS complex (LBBB ≥130 ms).

Anticoagulation therapy for AF reduces stroke risk by 60–70% compared to no therapy, representing one of the most important preventive interventions in cardiovascular medicine. DOAC therapy (apixaban, rivaroxaban, edoxaban, dabigatran) has largely replaced warfarin due to superior safety profiles for intracranial haemorrhage and simpler management without INR monitoring.

Catheter ablation of AF achieves freedom from AF at 12 months in approximately 60–75% of patients with paroxysmal AF after a single procedure, with higher rates after repeat procedures. Early rhythm control with ablation (EAST-AFNET 4 trial) demonstrated a 21% reduction in the composite outcome of cardiovascular death, stroke, and hospitalisation compared to late or rate-control strategies in patients with early-diagnosed AF and cardiovascular risk factors. SVT ablation achieves cure rates of 95%, eliminating the need for long-term drug therapy. ICD therapy reduces all-cause mortality by 23% in primary prevention patients with EF ≤35% (MADIT-II, SCD-HeFT trials).

Catheter ablation for AF carries defined procedural risks: cardiac tamponade (0.5–1.5%) — potentially requiring pericardiocentesis or surgical drainage; pulmonary vein stenosis (1–2%) with significant stenosis requiring balloon dilation; oesophageal injury including atrio-oesophageal fistula (rare, <0.1%, but highly fatal if delayed recognition); phrenic nerve injury (1–2% with cryoablation, typically transient); and thromboembolic events (stroke/TIA ~0.5–1%) despite peri-procedural anticoagulation. Vascular access complications (haematoma, pseudoaneurysm) occur in 1–3% of cases.

Antiarrhythmic drug side effects are class-specific: flecainide is contraindicated in structural heart disease due to proarrhythmia risk (CAST trial); amiodarone has significant multi-organ toxicity with long-term use (thyroid, lung, liver, cornea, peripheral neuropathy) requiring regular monitoring; sotalol requires QTc interval monitoring to prevent torsades de pointes. Anticoagulant therapy increases bleeding risk — major bleeding 2–3% per year on DOACs; intracranial haemorrhage 0.2–0.4% per year. Device implantation risks include pocket haematoma (2–5%), lead dislodgement (1–3%), infection (<1% but serious), and pneumothorax (<1%).

Following catheter ablation, patients typically remain in hospital for 24–48 hours for monitoring. Post-procedure anticoagulation is continued for a minimum of 2 months regardless of AF burden (risk of delayed cardiac inflammation and atrial stunning), and long-term anticoagulation is maintained based on CHA2DS2-VASc score rather than arrhythmia recurrence. A blanking period of 90 days is recognised post-ablation, during which early recurrences (often due to inflammation) do not predict long-term outcome. Rhythm monitoring at 3, 6, and 12 months — using ECG, Holter, or implantable loop recorder — assesses procedural success.

For device recipients, pacemaker battery longevity is 7–12 years; ICD devices 5–10 years. Routine follow-up includes device interrogation every 6–12 months. Patients should carry a device identification card and register with the manufacturer for safety alerts. MRI-conditional devices allow MRI investigations at 1.5T with appropriate safeguards. Post-discharge recovery after uncomplicated ablation involves 2–3 days rest, avoiding strenuous activity for 1 week, and return to driving per local DVLA/national regulations (typically 1 week for SVT/AF ablation, 6 months for VT ablation or ICD implant).

The cost of arrhythmia treatment varies considerably by modality and country. In the United States, catheter ablation for AF typically costs $25,000–50,000 including hospitalisation, electrophysiology laboratory fees, and device costs for 3D mapping systems. ICD implantation costs $30,000–60,000 in the US (device hardware alone: $15,000–30,000). In the UK, NHS provides ablation and ICD implantation at no cost to patients, though waiting times may extend 6–18 months. Ongoing anticoagulation with DOACs costs $200–400/month in the US without insurance.

Medical tourism for arrhythmia treatment offers substantial savings for privately funded patients. India's leading cardiology centres — Apollo Hospitals, Fortis, Narayana Health, Medanta — perform AF ablation procedures at $3,000–7,000 total including hospitalisation, using the same Carto 3D mapping, ThermoCool SmartTouch catheters, and CryoAblation systems as Western centres. ICD implantation costs $8,000–15,000 in India compared to $30,000–60,000 in the US. Singapore and Thailand offer ablation at $10,000–20,000 with internationally trained electrophysiologists.

For rate control in AF, the principal alternative to pharmacotherapy is AV node ablation with permanent pacemaker implantation — a palliative strategy that achieves excellent rate control by ablating the AV node and implanting a permanent pacemaker, converting an irregularly irregular arrhythmia to a device-controlled regular rhythm. This approach is reserved for patients with refractory rate control despite optimal pharmacotherapy.

For AF patients in whom catheter ablation is not appropriate, hybrid ablation — combining thoracoscopic surgical epicardial ablation with transcatheter endocardial ablation — offers an alternative for long-standing persistent AF. Convergent procedure and AtriClip left atrial appendage occlusion are additional surgical options. For rhythm control, newer antiarrhythmic options including dronedarone (safer than amiodarone but less effective) and vernakalant (IV, rapid cardioversion) provide additional pharmacological strategies. For VT in structural heart disease, surgical ventricular reconstruction and mechanical circulatory support (LVAD) address the underlying substrate when ablation has failed or is not feasible.